EyePoint Pharmaceuticals has fully enrolled its two Phase 3 wet AMD trials, LUGANO and LUCIA, with more than 900 patients and a first data readout expected mid-2026, while launching a pivotal Phase 3 program in diabetic macular edema consisting of two identical non-inferiority studies, COMO and CAPRI, with first dosing planned for the first quarter of 2026. The company also unveiled preclinical data suggesting that its investigational, twice-yearly, sustained-release TKI, DURAVYU, may act via dual mechanisms—blocking VEGF-driven vascular permeability and dampening IL-6–mediated inflammation—in both wet AMD and DME. An oversubscribed $172.5 million equity raise extends cash runway into the fourth quarter of 2027, funding the DME program through pivotal completion.
The strategic question is whether a local, bioerodible TKI with six-month redosing can materially shift treatment patterns in retinal disease now dominated by high-frequency anti-VEGF injections and newer extended-interval regimens. Non-inferiority to on-label 2 mg aflibercept over 52–56 weeks is an acceptable regulatory path, but market adoption will hinge on durability performance, rescue-injection rates, safety, and real-world adherence. If DURAVYU delivers clinically meaningful reductions in visit burden without compromising vision outcomes, it could force payers and retina practices to recalibrate around fewer chair-time events per patient. This operational and economic pivot has stalled past sustained-delivery attempts.
The timing matters. After the withdrawal of the port delivery system and setbacks for other long-acting approaches, the field has tilted back toward injections with improved durability, such as faricimab and high-dose aflibercept, while biosimilars pressure price points in earlier lines. A credible, in-office, twice-yearly option would directly challenge that equilibrium. For patients, fewer injections could reduce anxiety and missed workdays; for payers, the value proposition will rest on total cost of care, reduced procedure frequency, and maintained visual acuity. Retina specialists will weigh the promise of capacity relief against practice economics historically aligned with injection volume, making Medical Affairs engagement and evidence on quality of life, productivity, and HCP workflow crucial.
EyePoint is positioning DURAVYU to be the first to file among investigational sustained-release programs in wet AMD, and it is currently the only TKI in Phase 3 for DME. The dual-pathway narrative may resonate given the inflammatory components in DME and recalcitrant wet AMD, but TKIs carry class perceptions around intraocular inflammation that will require careful safety storytelling. Phase 2 VERONA signaled six-month durability with vision gains in DME after a single dose; Phase 3 will need to confirm consistency across broader populations, including treatment-naïve and previously treated patients, and quantify rescue rates versus an active control. Significantly, comparators are evolving: non-inferiority to 2 mg aflibercept might satisfy regulators, while leaving payers to ask how it stacks up against faricimab or 8 mg aflibercept in extended dosing paradigms.
From a capital markets standpoint, funding into late 2027 aligns with a potential 2027 approval window if 2026 data support an NDA, reducing near-term financing overhang and signaling investor appetite for late-stage ophthalmology assets. For business development teams, the asset’s regional licensing structure—e.g., China ophthalmic rights—creates partnering optionality outside China and a plausible M&A rationale for larger ophthalmology franchises seeking durable platforms post-PDS. Competitors will now calibrate trial design, dosing intervals, and head-to-head plans to defend share if DURAVYU’s data are clean.
The next inflection is precise: will mid-2026 wet AMD results demonstrate not just non-inferiority on BCVA but a compelling, rescue-sparing durability profile with a benign safety signal? If so, the center of gravity in retinal care could shift from marginal interval extensions to a true twice-yearly paradigm, redefining value narratives for patients, payers, and practices alike.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
